Any current/future new fundraising through debt or equity?

Funding for expansion plans in the U.S. and other regions will come from a mix of internal accruals, debt, and IPO proceeds. The company plans to use all three sources combined depending on the fund requirements. No specific mention of upcoming fundraising rounds, but IPO proceeds are indicated as part of the funding strategy, suggesting a recent or planned IPO. No additional explicit plans for new debt or equity fundraising were disclosed beyond this combined approach.

Any current/future capex/capital investment/strategic investment?

Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores. Capex split between US and India manufacturing facilities. In the US: - Four oral solid manufacturing lines planned, with the third line operational by Q3 FY26 and the fourth by year-end. - Expansion of US plant capacity from 1.2 billion to 2 billion units. India facility: - Strategic investment to cater to new markets (e.g., Brazil, Mexico, EU). Part of capex funding through internal accruals, part debt, and IPO proceeds. Some capex to spill into next year (around

Future growth expectations in sales/revenue/volumes?

Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. regulated market revenue going forward. FY26 revenue guidance is around INR 600-650 crores, a 50% growth year-on-year, with 100% net profit growth. CDMO segment expected to contribute about INR 200 crores in FY26 with 20%-30% CAGR growth in subsequent years. Emerging markets show strong growth with 32% Y-o-Y revenue increase; EBITDA expected to improve from 6% to mid-teens (~10-15%) by next year. Product launches in H2 FY26 will further boost sales, with peak impact expected in FY27. Total US manufacturing capacity expan

Future growth expectations in earnings/operating earnings/profits/EPS?

Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25. Profit after tax (PAT) projected to grow about 100% in FY26 compared to FY25. EBITDA margins are expected to stabilize around 25%-26% on an annualized basis. Emerging market business is targeting EBITDA margins to improve to around 15%-17% sustainably. The company anticipates mid-teen EBITDA margins in emerging markets by next year, with current year improving from 6% EBITDA. CDMO business expects continued robust growth of 20%-30% CAGR going forward. The company expects positive operating cas

Current/ Expected Orderbook/ Pending Orders?

Current CDMO-CMO order book stands at approximately USD 23 million as of the beginning of Q1FY26. The order book typically spans an execution timeframe of 12 to 18 months, with rolling and long-term contracts. The company maintains ongoing discussions with multiple partners, indicating potential for additional orders beyond the current book. Expected CDMO revenues for FY26 are around INR 200 crores, with growth visibility and confidence to meet this target. Future growth for CDMO-CMO is projected at a CAGR of 20% to 30%, with capacity additions underway to support pipeline expansion.

IN US

Sale is live|00:00:00left today

Senores Pharmaceuticals LtdQ2 FY25Pharmaceuticals & Biotechnology

Senores Pharmaceuticals Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,270P/E: 41.9Market Cap: ₹4.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. regulated market revenue going forward.
→FY26 revenue guidance is around INR 600-650 crores, a 50% growth year-on-year, with 100% net profit growth.
→CDMO segment expected to contribute about INR 200 crores in FY26 with 20%-30% CAGR growth in subsequent years.
→Emerging markets show strong growth with 32% Y-o-Y revenue increase; EBITDA expected to improve from 6% to mid-teens (~10-15%) by next year.
→Product launches in H2 FY26 will further boost sales, with peak impact expected in FY27.
→Total US manufacturing capacity expansion will support volume growth, including four lines by end of the year.
→Inorganic growth through ANDA acquisitions (20+ acquisitions done) will add to product portfolio and sales.
→Emerging market new product registrations (719 under registration) will fuel future growth.

Margin guidance

Category 3

→Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.
→Profit after tax (PAT) projected to grow about 100% in FY26 compared to FY25.
→EBITDA margins are expected to stabilize around 25%-26% on an annualized basis.
→Emerging market business is targeting EBITDA margins to improve to around 15%-17% sustainably.
→The company anticipates mid-teen EBITDA margins in emerging markets by next year, with current year improving from 6% EBITDA.
→CDMO business expects continued robust growth of 20%-30% CAGR going forward.
→The company expects positive operating cash flow going forward, with INR 11 crores positive in Q1FY26.
→Branded generics revenues expected to surpass INR 50 crores in FY26, contributing to profitability.
→The US regulated market business expects steady 20%-30% CAGR growth over next few years.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Funding for expansion plans in the U.S. and other regions will come from a mix of internal accruals, debt, and IPO proceeds.
→The company plans to use all three sources combined depending on the fund requirements.
→No specific mention of upcoming fundraising rounds, but IPO proceeds are indicated as part of the funding strategy, suggesting a recent or planned IPO.
→No additional explicit plans for new debt or equity fundraising were disclosed beyond this combined approach.

Order book

Yes

→Current CDMO-CMO order book stands at approximately USD 23 million as of the beginning of Q1FY26.
→The order book typically spans an execution timeframe of 12 to 18 months, with rolling and long-term contracts.
→The company maintains ongoing discussions with multiple partners, indicating potential for additional orders beyond the current book.
→Expected CDMO revenues for FY26 are around INR 200 crores, with growth visibility and confidence to meet this target.
→Future growth for CDMO-CMO is projected at a CAGR of 20% to 30%, with capacity additions underway to support pipeline expansion.
→Order book is considered firm but flexible, with some rollover and substitution of orders anticipated through the execution period.

Capex plans

Yes

→Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.
→Capex split between US and India manufacturing facilities.
→In the US:
→ - Four oral solid manufacturing lines planned, with the third line operational by Q3 FY26 and the fourth by year-end.
→ - Expansion of US plant capacity from 1.2 billion to 2 billion units.
→India facility:
→ - Strategic investment to cater to new markets (e.g., Brazil, Mexico, EU).
→Part of capex funding through internal accruals, part debt, and IPO proceeds.
→Some capex to spill into next year (around INR 50 crores).
→Focus on backward integration via API manufacturing facility in Chhatral (~100-150 metric tons capacity), filing DMF for FDA approval.
→Ongoing inorganic growth by acquiring ANDAs, with 20+ acquisitions so far, targeting product portfolio expansion aligned with business strategy.

How does Senores Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Senores Pharmaceuticals Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Senores Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio